ClinicalTrials.gg
CompletedNCT01511874Updated Sep 23, 2015

Efficacy and Safety Study of ELIGARD 22.5mg With Prostate Cancer

A Phase 4 interventional study of ELIGARD 22.5mg in Prostate Cancer, sponsored by HanAll BioPharma Co., Ltd.. Completed at 1 site in Korea, Republic of. Open to male participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2015-09-23.

Sponsored by HanAll BioPharma Co., Ltd. (part of Daewoong Pharmaceutical Co. LTD.) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
42
Allocation
Not applicable
Ages
20 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 198 studies in Prostatic Neoplasms with a site in Korea, Republic of — 49 open to participants now, 81 under way, 37 of them phase 3. Prostatic Neoplasms · Korea, Republic of.

Enrollment
144th of 165
42 · median 208
Started
2011
with 5 others
Phase 4
8 of 198
2 open now
Registered
31st of 198
by date

Among the 198 studies in Prostatic Neoplasms with a site in Korea, Republic of, this one is the 144th largest by enrollment of the 165 interventional ones that give a count, is one of 6 that started in 2011, is one of 8 in phase 4, and was the 31st registered.

Prostatic Neoplasms

7,052 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

49 of the 198 studies in Prostatic Neoplasms with a site in Korea, Republic of are open now. Recruiting first, the newest first:

44 more — sign in →

All 49 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 20 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 198 studies in Prostatic Neoplasms with a site in Korea, Republic of, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate efficacy and safety of ELIGARD 22.5mg in the treatment of subjects with prostate cancer.

03

Conditions studied

  • Prostate Cancer

Browse trials for

Keywords

  • ELIGARD
  • Prostate cancer
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male of 20 years or above
  • Subject with prostate cancer with TNM stage T2\~4NxMx
  • Blood testosterone concentration ≥ 100ng/dl
  • ≤ 1.5xULN, transaminase ≤ 2.5xULN
  • WHO performance status ≤ 2
  • Signed written

Exclusion criteria

Exclusion Criteria:

  • Hormone- Prostate cancer
  • Another primary malignant tumor except for prostate cancer
  • Other conditions which in the opinion of the investigator preclude enrollment into the study
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
42 participants (actual)

Study arms

  • Experimental
    ELIGRAD 22.5mg

    a subcutaneous injection of ELIGARD 22.5mg at 0 and 12weeks

    Drug: ELIGARD 22.5mg

Interventions

  • a subcutaneous injection of ELIGARD 22.5mg at 0 and 12weeks

    Also known as: ELIGARD

06

What researchers measure

Primary outcomes

  1. Ratio of subjects whose blood testosterone concentration is maintained below 50ng/dl at 4 weeks after injection of ELIGARD 22.5mg

    Time frame: 4weeks

Secondary outcomes

  1. Ratio of subjects whose blood testosterone concentration is maintained below 50ng/dL until 24weeks

    Time frame: 24weeks

  2. Ratio of subjects whose blood testosterone concentration exceed 50ng/dL until 24weeks

    Time frame: 24weeks

  3. Change in self assessment scale grade

    Time frame: 0,4, 8, 12, 24 weeks

  4. Ratio of subjects whose blood testosterone concentration is below 20ng/dL at 4weeks and 24weeks

    Time frame: 4, 24 weeks

  5. Change in ECOG performance status

    Time frame: 0,4,8,12, 24weeks

  6. Change in blood prostate-specific antigen

    Time frame: 0,4,8,12,24 weeks

  7. Change in QoL_EPIC grade

    Time frame: 0,12, 24weeks

  8. Change in penile length

    Time frame: screening, 12, 24weeks

  9. Change in testicular volume

    Time frame: screening, 12, 24weeks

07

Study locations

1 site
  • Department of Urology,Yonsei University,College of Medicine, Gangnam Severance Hospital
    Seoul, Korea, Republic of
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2011, a primary completion of May 2013 and a completion of Dec 2013. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 13, 2012
First posted
Jan 19, 2012
Start
Jan 2011
Primary completionActual
May 2013
CompletionActual
Dec 2013
Last update
Sep 23, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 23, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01511874
Responsible party
Sponsor
First posted
Jan 19, 2012
Start date
Jan 2011
Primary completion
May 2013
Completion
Dec 2013
Last update
Sep 23, 2015

Study contacts

Byung Ha Chung, Medicine
principal investigator · Department of Urology,Yonsei University,College of Medicine, Gangnam Severance Hospital

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Luprolide acetate gel depot

Start the discussion